Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Joseph T. Crossno is active.

Publication


Featured researches published by Joseph T. Crossno.


Journal of Clinical Investigation | 2006

Rosiglitazone promotes development of a novel adipocyte population from bone marrow-derived circulating progenitor cells.

Joseph T. Crossno; Susan M. Majka; Todd J. Grazia; Ronald G. Gill; Dwight J. Klemm

Obesity and weight gain are characterized by increased adipose tissue mass due to an increase in the size of individual adipocytes and the generation of new adipocytes. New adipocytes are believed to arise from resident adipose tissue preadipocytes and mesenchymal progenitor cells. However, it is possible that progenitor cells from other tissues, in particular BM, could also contribute to development of new adipocytes in adipose tissue. We tested this hypothesis by transplanting whole BM cells from GFP-expressing transgenic mice into wild-type C57BL/6 mice and subjecting them to a high-fat diet or treatment with the thiazolidinedione (TZD) rosiglitazone (ROSI) for several weeks. Histological examination of adipose tissue or FACS of adipocytes revealed the presence of GFP(+) multilocular (ML) adipocytes, whose number was significantly increased by ROSI treatment or high-fat feeding. These ML adipocytes expressed adiponectin, perilipin, fatty acid-binding protein (FABP), leptin, C/EBPalpha, and PPARgamma but not uncoupling protein-1 (UCP-1), the CD45 hematopoietic lineage marker, or the CDllb monocyte marker. They also exhibited increased mitochondrial content. Appearance of GFP(+) ML adipocytes was contemporaneous with an increase in circulating levels of mesenchymal and hematopoietic progenitor cells in ROSI-treated animals. We conclude that TZDs and high-fat feeding promote the trafficking of BM-derived circulating progenitor cells to adipose tissue and their differentiation into ML adipocytes.


Journal of Biological Chemistry | 2006

Antitumorigenic Effect of Wnt 7a and Fzd 9 in Non-small Cell Lung Cancer Cells Is Mediated through ERK-5-dependent Activation of Peroxisome Proliferator-activated Receptor γ

Robert A. Winn; Michelle Van Scoyk; Mandy Hammond; Karen J. Rodriguez; Joseph T. Crossno; Lynn E. Heasley; Raphael A. Nemenoff

The Wnt pathway is critical for normal development, and mutation of specific components is seen in carcinomas of diverse origins. The role of this pathway in lung tumorigenesis has not been clearly established. Recent studies from our laboratory indicate that combined expression of the combination of Wnt 7a and Frizzled 9 (Fzd 9) in Non-small Cell Lung Cancer (NSCLC) cell lines inhibits transformed growth. We have also shown that increased expression of peroxisome proliferator-activated receptor γ (PPARγ) inhibits transformed growth of NSCLC and promotes epithelial differentiation of these cells. The goal of this study was to determine whether the effects of Wnt 7a/Fzd 9 were mediated through PPARγ. We found that Wnt 7a and Fzd 9 expression led to increased PPARγ activity. This effect was not mediated by altered expression of the protein. Wnt 7a and Fzd 9 expression resulted in activation of ERK5, which was required for PPARγ activation in NSCLC. SR 202, a known PPARγ inhibitor, blocked the increase in PPARγ activity and restored anchorage-independent growth in NSCLC expressing Wnt 7a and Fzd 9. SR 202 also reversed the increase in E-cadherin expression mediated by Wnt 7a and Fzd 9. These data suggest that ERK5-dependent activation of PPARγ represents a major effector pathway mediating the anti-tumorigenic effects of Wnt 7a and Fzd 9 in NSCLC.


Circulation Research | 2008

Targeted Deletion of PTEN in Smooth Muscle Cells Results in Vascular Remodeling and Recruitment of Progenitor Cells Through Induction of Stromal Cell–Derived Factor-1α

Raphael A. Nemenoff; Peter Simpson; Seth B. Furgeson; Nihal Kaplan-Albuquerque; Joseph T. Crossno; Pamela J. Garl; James K. Cooper; Mary C.M. Weiser-Evans

We previously showed that changes in vascular smooth muscle cell (SMC) PTEN/Akt signaling following vascular injury are associated with increased SMC proliferation and neointima formation. In this report, we used a genetic model to deplete PTEN specifically in SMCs by crossing PTENLoxP/LoxP mice to mice expressing Cre recombinase under the control of the SM22&agr; promoter. PTEN was downregulated with increases in phosphorylated Akt in major vessels, hearts, and lungs of mutant mice. SMC PTEN depletion promoted widespread medial SMC hyperplasia, vascular remodeling, and histopathology consistent with pulmonary hypertension. Increased vascular deposition of the chemokine stromal cell–derived factor (SDF)-1&agr; and medial and intimal cells coexpressing SM-&agr;-actin and CXCR4, the SDF-1&agr; receptor, was detected in SMC PTEN-depleted mice. PTEN deficiency in cultured aortic SMCs induced autocrine growth through increased production of SDF-1&agr;. Blocking SDF-1&agr; attenuated autocrine growth and blocked growth of control SMCs induced by conditioned media from PTEN-deficient SMCs. In addition, SMC PTEN deficiency enhanced progenitor cell migration toward SMCs through increased SDF-1&agr; production. SDF-1&agr; production by other cell types is regulated by the transcription factor hypoxia-inducible factor (HIF)-1&agr;. We found SMC nuclear HIF-1&agr; expression in PTEN-depleted mice and increased nuclear HIF-1&agr; in PTEN-deficient SMCs. Small interfering RNA–mediated downregulation of HIF-1&agr; reversed SDF-1&agr; induction by PTEN depletion and inhibition of phosphatidylinositol 3-kinase signaling blocked HIF-1&agr; and SDF-1&agr; upregulation induced by PTEN depletion. Our data show that SMC PTEN inactivation establishes an autocrine growth loop and increases progenitor cell recruitment through a HIF-1&agr;–mediated SDF-1&agr;/CXCR4 axis, thus identifying PTEN as a target for the inhibition of pathological vascular remodeling.


Journal of Cardiovascular Pharmacology | 2011

Reduction of Reactive Oxygen Species Prevents Hypoxia-Induced CREB Depletion in Pulmonary Artery Smooth Muscle Cells

Dwight J. Klemm; Susan M. Majka; Joseph T. Crossno; John C. Psilas; Jane E.B. Reusch; Chrystelle V. Garat

Hypoxia-induced pulmonary arterial hypertension (PAH) is a deadly disease characterized by progressive remodeling and persistent vasoconstriction of the pulmonary arterial system. Remodeling of the pulmonary artery (PA) involves smooth muscle cell (SMC) proliferation, hypertrophy, migration, and elevated extracellular matrix (ECM) production elicited by mitogens and oxidants produced in response to hypoxic insult. We previously reported that the transcription factor cAMP response element binding protein (CREB) is depleted in medial PA SMCs in remodeled, hypertensive vessels in rats or calves exposed to chronic hypoxia. In culture, CREB loss can be induced in PA SMCs by exogenous oxidants or platelet-derived growth factor. Forced depletion of CREB with small interfering RNA (siRNA) in PA SMCs is sufficient to induce their proliferation, hypertrophy, migration, dedifferentiation, and ECM production. This suggests that oxidant and/or mitogen-induced loss of CREB in medial SMCs is, in part, responsible for PA thickening. Here, we tested whether oxidant scavengers could prevent the loss of CREB in PA SMCs and inhibit SMC proliferation, migration, and ECM production using in vitro and in vivo models. Exposure of PA SMCs to hypoxia induced hydrogen peroxide (H2O2) production and loss of CREB. Treatment of SMCs with exogenous H2O2 or a second oxidant, Sin-1, elicited CREB depletion under normoxic conditions. Exogenous H2O2 also induced SMC proliferation, migration, and increased elastin levels as did forced depletion of CREB. In vivo, hypoxia-induced thickening of the PA wall was suppressed by the superoxide dismutase mimetic, Tempol, which also prevented the loss of CREB in medial SMCs. Tempol also reduced hypoxia-induced SMC proliferation and elastin deposition in the PA. The data indicate that CREB levels in the arterial wall are regulated in part by oxidants produced in response to hypoxia and that CREB plays a crucial role in regulating SMC phenotype and PA remodeling.


American Journal of Physiology-heart and Circulatory Physiology | 2013

MAP kinase kinase kinase-2 (MEKK2) regulates hypertrophic remodeling of the right ventricle in hypoxia-induced pulmonary hypertension

R. Dale Brown; S. Kelly Ambler; Min Li; Timothy M. Sullivan; Lauren N. Henry; Joseph T. Crossno; Carlin S. Long; Timothy P. Garrington; Kurt R. Stenmark

Pulmonary hypertension (PH) results in pressure overload of the right ventricle (RV) of the heart, initiating pathological RV remodeling and ultimately leading to right heart failure. Substantial research indicates that signaling through the MAPK superfamily mediates pathological cardiac remodeling. These considerations led us to test the hypothesis that the regulatory protein MAPKKK-2 (MEKK2) contributes to RV hypertrophy in hypoxia-induced PH. Transgenic mice with global knockout of MEKK2 (MEKK2(-/-) mice) and age-matched wild-type (WT) mice were exposed to chronic hypobaric hypoxia (10% O(2), 6 wk) and compared with animals under normoxia. Exposure to chronic hypoxia induced PH in WT and MEKK2(-/-) mice. In response to PH, WT mice showed RV hypertrophy, demonstrated as increased ratio of RV weight to body weight, increased RV wall thickness at diastole, and increased cardiac myocyte size compared with normoxic control animals. In contrast, each of these measures of RV hypertrophy seen in WT mice after chronic hypoxia was attenuated in MEKK2(-/-) mice. Furthermore, chronic hypoxia elicited altered programs of hypertrophic and inflammatory gene expression consistent with pathological RV remodeling in WT mice; MEKK2 deletion selectively inhibited inflammatory gene expression compared with WT mice. The actions of MEKK2 were mediated in part through regulation of the abundance and phosphorylation of its effector, ERK5. In conclusion, signaling by MEKK2 contributes to RV hypertrophy and altered myocardial inflammatory gene expression in response to hypoxia-induced PH. Therapies targeting MEKK2 may protect the myocardium from hypertrophy and pathological remodeling in human PH.


Journal of Cardiovascular Pharmacology | 2010

Thiazolidinediones prevent PDGF-BB-induced CREB depletion in pulmonary artery smooth muscle cells by preventing upregulation of casein kinase 2 alpha' catalytic subunit.

Chrystelle V. Garat; Joseph T. Crossno; Timothy M. Sullivan; Jane E.B. Reusch; Dwight J. Klemm

Background: The transcription factor CREB is diminished in smooth muscle cells (SMCs) in remodeled, hypertensive pulmonary arteries (PAs) in animals exposed to chronic hypoxia. Forced depletion of cyclic adenosine monophosphate response element binding protein (CREB) in PA SMCs stimulates their proliferation and migration in vitro. Platelet-derived growth factor (PDGF) produced in the hypoxic PA wall promotes CREB proteasomal degradation in SMCs via phosphatidylinositol-3-kinase/Akt signaling, which promotes phosphorylation of CREB at 2 casein kinase 2 (CK2) sites. Here we tested whether thiazolidinediones, agents that inhibit hypoxia-induced PA remodeling, attenuate SMC CREB loss. Methods: Depletion of CREB and changes in casein kinase 2 catalytic subunit expression and activity were measured in PA SMC treated with PDGF. PA remodeling and changes in medial PA CREB and casein kinase 2 levels were evaluated in lung sections from rats exposed to hypoxia for 21 days. Results: We found that the thiazolidinedione rosiglitazone prevented PA remodeling and SMC CREB loss in rats exposed to chronic hypoxia. Likewise, the thiazolidinedione troglitazone blocked PA SMC proliferation and CREB depletion induced by PDGF in vitro. Thiazolidinediones did not repress Akt activation by hypoxia in vivo or by PDGF in vitro. However, PDGF-induced CK2 α′ catalytic subunit expression and activity in PA SMCs, and depletion of CK2 α′ subunit prevented PDGF-stimulated CREB loss. Troglitazone inhibited PDGF-induced CK2 α′ subunit expression in vitro and rosiglitazone blocked induction of CK2 catalytic subunit expression by hypoxia in PA SMCs in vivo. Conclusion: We conclude that thiazolidinediones prevent PA remodeling in part by suppressing upregulation of CK2 and loss of CREB in PA SMCs.


American Journal of Transplantation | 2011

Prolongation of cardiac allograft survival by a novel population of autologous CD117+ bone marrow-derived progenitor cells

Todd J. Grazia; Robert J. Plenter; Helen M. Lepper; Francisco Victorino; Shelley D. Miyamoto; Joseph T. Crossno; Biagio A. Pietra; Ronald G. Gill; Martin R. Zamora

Autologous CD117+ progenitor cells (PC) have been successfully utilized in myocardial infarction and ischemic injury, potentially through the replacement/repair of damaged vascular endothelium. To date, such cells have not been used to enhance solid organ transplant outcome. In this study, we determined whether autologous bone marrow‐derived CD117+PC could benefit cardiac allograft survival, possibly by replacing donor vascular cells. Autologous, positively selected CD117+PC were administered posttransplantation and allografts were assessed for acute rejection. Although significant generation of recipient vascular cell chimerism was not observed, transferred PC disseminated both to the allograft and to peripheral lymphoid tissues and facilitated a significant, dose‐dependent prolongation of allograft survival. While CD117+PC dramatically inhibited alloreactive T cell proliferation in vitro, this property did not differ from nonprotective CD117− bone marrow populations. In vivo, CD117+ PC did not significantly inhibit T cell alloreactivity or increase peripheral regulatory T cell numbers. Thus, rather than inhibiting adaptive immunity to the allograft, CD117+ PC may play a cytoprotective role in prolonging graft survival. Importantly, autologous CD117+PC appear to be distinct from bone marrow‐derived mesenchymal stem cells (MSC) previously used to prolong allograft survival. As such, autologous CD117+PC represent a novel cellular therapy for promoting allograft survival.


American Journal of Physiology-lung Cellular and Molecular Physiology | 2004

Hypoxia-induced pulmonary artery adventitial remodeling and neovascularization: contribution of progenitor cells

Neil J. Davie; Joseph T. Crossno; Maria G. Frid; Stephen Hofmeister; John T. Reeves; Dallas M. Hyde; Todd C. Carpenter; Jacqueline A. Brunetti; Ian McNiece; Kurt R. Stenmark


American Journal of Physiology-lung Cellular and Molecular Physiology | 2007

Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling

Joseph T. Crossno; Chrystelle V. Garat; Jane E.B. Reusch; Kenneth G. Morris; Edward C. Dempsey; Ivan F. McMurtry; Kurt R. Stenmark; Dwight J. Klemm


American Journal of Physiology-lung Cellular and Molecular Physiology | 2007

Mice deficient in galectin-1 exhibit attenuated physiological responses to chronic hypoxia-induced pulmonary hypertension

D. Case; David Irwin; C. Ivester; Julie Harral; K. Morris; M. Imamura; M. Roedersheimer; A. Patterson; Michelle Carr; Moira Hagen; M. Saavedra; Joseph T. Crossno; Katharine A. Young; Edward C. Dempsey; F. Poirier; James West; Susan M. Majka

Collaboration


Dive into the Joseph T. Crossno's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Dwight J. Klemm

University of Colorado Denver

View shared research outputs
Top Co-Authors

Avatar

Chrystelle V. Garat

University of Colorado Denver

View shared research outputs
Top Co-Authors

Avatar

Jane E.B. Reusch

University of Colorado Denver

View shared research outputs
Top Co-Authors

Avatar

Kurt R. Stenmark

University of Colorado Denver

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

James West

Vanderbilt University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ronald G. Gill

University of Colorado Denver

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge